- Home
- SPHR vs KNSA Comparison
SPHR vs KNSA Comparison
Compare SPHR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- KNSA
- Stock Information
- Founded
- SPHR 2020
- KNSA 2015
- Country
- SPHR United States
- KNSA United Kingdom
- Employees
- SPHR N/A
- KNSA N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- SPHR Consumer Discretionary
- KNSA Health Care
- Exchange
- SPHR Nasdaq
- KNSA Nasdaq
- Market Cap
- SPHR 1.4B
- KNSA 1.5B
- IPO Year
- SPHR N/A
- KNSA 2018
- Fundamental
- Price
- SPHR $31.00
- KNSA $22.16
- Analyst Decision
- SPHR Buy
- KNSA Strong Buy
- Analyst Count
- SPHR 9
- KNSA 6
- Target Price
- SPHR $48.44
- KNSA $37.17
- AVG Volume (30 Days)
- SPHR 1.0M
- KNSA 670.3K
- Earning Date
- SPHR 03-03-2025
- KNSA 04-22-2025
- Dividend Yield
- SPHR N/A
- KNSA N/A
- EPS Growth
- SPHR N/A
- KNSA N/A
- EPS
- SPHR N/A
- KNSA N/A
- Revenue
- SPHR $1,072,406,000.00
- KNSA $423,239,000.00
- Revenue This Year
- SPHR $6.49
- KNSA $37.21
- Revenue Next Year
- SPHR $7.53
- KNSA $1.38
- P/E Ratio
- SPHR N/A
- KNSA N/A
- Revenue Growth
- SPHR 48.26
- KNSA 56.60
- 52 Week Low
- SPHR $30.63
- KNSA $16.56
- 52 Week High
- SPHR $50.88
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- SPHR 19.73
- KNSA 64.22
- Support Level
- SPHR $34.56
- KNSA $20.39
- Resistance Level
- SPHR $44.44
- KNSA $22.14
- Average True Range (ATR)
- SPHR 2.63
- KNSA 0.94
- MACD
- SPHR -1.30
- KNSA 0.20
- Stochastic Oscillator
- SPHR 2.30
- KNSA 79.14
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.